SAB Biotherapeutics, Inc. (NASDAQ:SABS) Stock Has Average Target Price of $12.00 According to Analysts

Posted by on Oct 3rd, 2026

SAB Biotherapeutics, Inc. (NASDAQ:SABS – Get Free Report) has earned an average recommendation of “Moderate Buy” from the eleven ratings firms that are presently covering the stock, MarketBeat.com reports. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and nine have issued a buy rating on the company. The average 1-year price target among brokerages that have issued a report on the stock in the last year is $12.00.

A number of equities research analysts recently commented on SABS shares. HC Wainwright reaffirmed a “buy” rating and set a $10.00 target price on shares of SAB Biotherapeutics in a report on Monday, June 15th. Barclays started coverage on SAB Biotherapeutics in a report on Wednesday, June 24th. They issued an “overweight” rating and a $13.00 price objective for the company. Leerink Partners raised their price objective on shares of SAB Biotherapeutics from $7.00 to $12.00 and gave the stock an “outperform” rating in a research note on Monday, June 15th. Weiss Ratings upgraded SAB Biotherapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Thursday, September 17th. Finally, Chardan Capital upped their price target on SAB Biotherapeutics from $14.00 to $16.00 and gave the company a “buy” rating in a research report on Wednesday, June 17th.

Read Our Latest Report on SAB Biotherapeutics

Institutional Trading of SAB Biotherapeutics

A number of institutional investors and hedge funds have recently bought and sold shares of the business. PNC Financial Services Group Inc. purchased a new position in SAB Biotherapeutics in the first quarter valued at $29,000. Fifth Lane Capital LP purchased a new position in SAB Biotherapeutics in the fourth quarter valued at $56,000. IFP Advisors Inc acquired a new stake in SAB Biotherapeutics in the second quarter valued at $151,000. Bank of America Corp DE raised its stake in SAB Biotherapeutics by 424.8% in the first quarter. Bank of America Corp DE now owns 55,697 shares of the company’s stock valued at $213,000 after buying an additional 45,084 shares in the last quarter. Finally, Kestra Advisory Services LLC lifted its holdings in SAB Biotherapeutics by 434.6% during the 1st quarter. Kestra Advisory Services LLC now owns 61,741 shares of the company’s stock worth $236,000 after buying an additional 50,191 shares during the last quarter. 7.82% of the stock is currently owned by hedge funds and other institutional investors.

SAB Biotherapeutics Price Performance

NASDAQ SABS opened at $2.98 on Wednesday. The firm’s fifty day simple moving average is $3.59 and its two-hundred day simple moving average is $3.69. The firm has a market capitalization of $271.15 million, a P/E ratio of -2.29 and a beta of 0.58. The company has a current ratio of 9.22, a quick ratio of 9.22 and a debt-to-equity ratio of 0.01. SAB Biotherapeutics has a 12-month low of $1.97 and a 12-month high of $5.15.

SAB Biotherapeutics (NASDAQ:SABS – Get Free Report) last announced its earnings results on Thursday, August 6th. The company reported ($0.28) earnings per share for the quarter, hitting the consensus estimate of ($0.28). Analysts forecast that SAB Biotherapeutics will post -1.17 EPS for the current fiscal year.

About SAB Biotherapeutics

(Get Free Report)

SAB Biotherapeutics, Inc is a clinical-stage biopharmaceutical company developing targeted antibody-based medicines for infectious diseases and immune-mediated conditions. The company’s approach is designed to produce fully human polyclonal antibodies that can recognize and neutralize multiple targets associated with a disease.

SAB’s technology platform, known as DiversitAb, uses genetically engineered cattle that are capable of producing human antibodies. Antibodies harvested from the animals’ plasma are evaluated for potential use as therapeutics.

Read More

Analyst Recommendations for SAB Biotherapeutics (NASDAQ:SABS)

Receive News & Ratings for SAB Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SAB Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.